KAMPALA, April 23, 2025 –– Dr. Matthias Magoola, Founder of Dei Biopharma, has been honoured with the prestigious Pharma Ratna Universe Award, India’s most coveted recognition in the biopharma and healthcare sector.
The award was accepted on Magoola’s behalf by Olivia Kemigisa, Head of Human Capital at Dei Biopharma Ltd, during the award ceremony held on 20 April at the Taj Skyline in Ahmedabad, Gujarat, India.
In their official citation, the organisers of Pharma Ratna praised Dr Magoola for his outstanding contributions to the industry and for building Dei Biopharma from the ground up into a company valued at USD 2.5 billion by 2025.
“A man who has made the whole of Africa proud with his visionary approach. He started his career from nothing and is now a billionaire,” the citation stated.
It continued: “His vision is to free Africa from malaria and other deadly diseases. He owns Africa’s largest pharmaceutical and biotech company.”
A distinguished Ugandan scientist, Magoola has been recognised for his groundbreaking work in pharmaceuticals and vaccine development, a feat that has brought pride to both Uganda and the wider African continent.
Pharma Ratna further lauded Magoola, noting that the award was not only a personal achievement but a symbolic victory for Uganda, Africa, and “every dreamer who believes in building global impact from the ground up.”
Dei Biopharma Ltd’s Chief Executive Officer, Hitesh Upreti, highlighted the broader significance of the award:
“This award is a salute to the spirit of innovation, resilience, and purpose that Dr Magoola embodies. We are grateful to Pharma Ratna Universe 2025 for recognising African excellence on this global stage. Our commitment has only grown stronger—we aim to rise higher, reach farther, and serve better.”
The award follows recent recognition from President Yoweri Museveni, who applauded Magoola for his exceptional achievements in medical innovation. Museveni noted that Magoola had filed over 100 patents with the United States Patent and Trademark Office [USPTO], targeting a wide array of diseases.
“I am pleased to learn that he has filed over 100 patents with the United States Patent Office for treating various diseases, some of which have already been granted,” Museveni said.
He also confirmed the Ugandan government’s support in facilitating regulatory processes to ensure that Dei Biopharma’s medicines can be licensed and produced locally for both domestic and international markets.
“The government will assist his company with the necessary accreditation processes to obtain licences for local production and export,” Museveni assured.
This endorsement comes amid growing global attention on Dei Biopharma, particularly following the granting of a U.S. patent for a novel cancer treatment developed under Magoola’s leadership.
Buy your copy of thecooperator magazine from one of our country-wide vending points or an e-copy on emag.thecooperator.news
Views: 6
